![tessera therapeutics stocks tessera therapeutics stocks](https://finformer.net/preview/security/BBG00HFX36F0.jpg)
“Tessera will benefit immensely from Mike’s extensive leadership experience and expertise in both R&D and commercial, especially as we look ahead to bringing GENE WRITING into the clinic,” said Geoffrey von Maltzahn, Ph.D., Co-Founder and Board Chair of Tessera Therapeutics. Geoffrey von Maltzahn, who served as Tessera’s founding CEO, will transition to Board Chair and continue to stay closely involved in the company’s efforts to transform genetic medicine with treatments for diseases and vulnerabilities through its GENE WRITING platforms. Tessera’s GENE WRITING technology consists of multiple platforms designed to offer scientists and clinicians the ability to write therapeutic messages into the human genome, thereby curing diseases at their source. “Mike’s R&D expertise and years of experience leading innovative strategies for notable biopharmaceutical companies will help drive Tessera’s growth and the translation of its pioneering technology.”Īfeyan added, “Under Geoff von Maltzahn’s leadership as founding CEO of Tessera, the company has created strong platform foundations and is poised for the next phase of growth as Geoff transitions into the Board Chair role.” “Mike will play a critical role at Flagship as CEO-Partner and, through that position, take on the role as CEO of Tessera, a company revolutionizing genetic medicine,” said Noubar Afeyan, Ph.D., Founder and CEO of Flagship Pioneering and Tessera Co-Founder and Board member. Prior to Amgen, he was Senior Director at Merck & Co., Inc., responsible for leading research in multiple areas, including clinical genomics, molecular profiling, and experimental medicine. Severino held several senior leadership roles at Amgen, leading to his appointment as Senior Vice President and Corporate Chief Medical Officer where he oversaw the company's global clinical research efforts. In his roles at AbbVie as Executive Vice President of Research and Development, Chief Scientific Officer and most recently Vice Chairman and President, he led efforts to build a strong pipeline and advance promising science for patients in the areas of hematologic oncology, immunology, and neuroscience. Severino brings more than two decades of biopharmaceutical leadership to Tessera, having led the strategy behind research, development, registration, and commercialization of more than a dozen FDA-approved therapies. Severino, who was previously Vice Chairman and President of AbbVie, also serves as a Flagship Pioneering CEO-Partner.ĭr. The latest funding round was co-led by Alaska Permanent Fund Corporation, Altitude Life Science Ventures, and SoftBank Vision Fund 2, with participation from Qatar Investment Authority and others.Michael Severino, M.D., Joins Flagship Pioneering-Founded Tessera Therapeutics as Chief Executive Officerįlagship Pioneering, the bioplatform innovation company, and Tessera Therapeutics, the biotechnology company pioneering GENE WRITING technology, today announced that Michael Severino, M.D., has joined Tessera as Chief Executive Officer. “The company is still connected to Flagship for many core functions, and we are building out the executive team so the company’s operations can stand entirely on their own,” von Maltzahn said. With the new funding, Tessera will grow its 50-person team by about 100 employees this year, set up manufacturing and automation capabilities, and be better positioned to support multiple clinical trials in the future. “Today it is safe to say we are building technology with the potential to address many dozens of distinct diseases.” “We haven’t announced the specific programs that will be at the front of the pipeline,” he said. While clinical trials are likely years away, von Maltzahn said the recent round is about taking the company to a point where it has a “big portfolio of therapeutics that are ready to transition” there. “You could imagine gene writing into a subset of your cells, a sequence that protects you from ever getting Alzheimer’s or cardiovascular disease,” he said. The startup has yet to disclose which diseases it is going after, but its method could potentially be used to treat cardiovascular, oncological, neurodegenerative, and infectious diseases.